BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 22457235)

  • 1. Tumour recurrence and enlargement in patients with craniopharyngioma with and without GH replacement therapy during more than 10 years of follow-up.
    Olsson DS; Buchfelder M; Wiendieck K; Kremenevskaja N; Bengtsson BÅ; Jakobsson KE; Jarfelt M; Johannsson G; Nilsson AG
    Eur J Endocrinol; 2012 Jun; 166(6):1061-8. PubMed ID: 22457235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparing progression of non-functioning pituitary adenomas in hypopituitarism patients with and without long-term GH replacement therapy.
    Olsson DS; Buchfelder M; Schlaffer S; Bengtsson BA; Jakobsson KE; Johannsson G; Nilsson AG
    Eur J Endocrinol; 2009 Nov; 161(5):663-9. PubMed ID: 19734242
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GH replacement does not increase the risk of recurrence in patients with craniopharyngioma.
    Karavitaki N; Warner JT; Marland A; Shine B; Ryan F; Arnold J; Turner HE; Wass JA
    Clin Endocrinol (Oxf); 2006 May; 64(5):556-60. PubMed ID: 16649976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GH and Childhood-onset Craniopharyngioma: When to Initiate GH Replacement Therapy?
    Nguyen Quoc A; Beccaria K; González Briceño L; Pinto G; Samara-Boustani D; Stoupa A; Beltrand J; Besançon A; Thalassinos C; Puget S; Blauwblomme T; Alapetite C; Bolle S; Doz F; Grill J; Dufour C; Bourdeaut F; Abbou S; Guerrini-Rousseau L; Leruste A; Brabant S; Cavadias I; Viaud M; Boddaert N; Polak M; Kariyawasam D
    J Clin Endocrinol Metab; 2023 Jul; 108(8):1929-1936. PubMed ID: 36794424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence of primary cancers and intracranial tumour recurrences in GH-treated and untreated adult hypopituitary patients: analyses from the Hypopituitary Control and Complications Study.
    Child CJ; Conroy D; Zimmermann AG; Woodmansee WW; Erfurth EM; Robison LL
    Eur J Endocrinol; 2015 Jun; 172(6):779-90. PubMed ID: 25810462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term safety of growth hormone replacement after CNS irradiation.
    Mackenzie S; Craven T; Gattamaneni HR; Swindell R; Shalet SM; Brabant G
    J Clin Endocrinol Metab; 2011 Sep; 96(9):2756-61. PubMed ID: 21715535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Physiological growth hormone replacement and rate of recurrence of craniopharyngioma: the Genentech National Cooperative Growth Study.
    Smith TR; Cote DJ; Jane JA; Laws ER
    J Neurosurg Pediatr; 2016 Oct; 18(4):408-412. PubMed ID: 27286443
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of Growth Hormone Replacement Therapy in Childhood-Onset Craniopharyngioma: A Systematic Review and Cohort Study.
    van Schaik J; Kormelink E; Kabak E; van Dalen EC; Schouten-van Meeteren AYN; de Vos-Kerkhof E; Bakker B; Fiocco M; Hoving EW; Tissing WJE; van Santen HM
    Neuroendocrinology; 2023; 113(10):987-1007. PubMed ID: 37231961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor Recurrence or Regrowth in Adults With Nonfunctioning Pituitary Adenomas Using GH Replacement Therapy.
    van Varsseveld NC; van Bunderen CC; Franken AA; Koppeschaar HP; van der Lely AJ; Drent ML
    J Clin Endocrinol Metab; 2015 Aug; 100(8):3132-9. PubMed ID: 26057181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Physiologic Growth Hormone-Replacement Therapy and Craniopharyngioma Recurrence in Pediatric Patients: A Meta-Analysis.
    Alotaibi NM; Noormohamed N; Cote DJ; Alharthi S; Doucette J; Zaidi HA; Mekary RA; Smith TR
    World Neurosurg; 2018 Jan; 109():487-496.e1. PubMed ID: 28987837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Growth hormone replacement therapy in children with medulloblastoma: use and effect on tumor control.
    Packer RJ; Boyett JM; Janss AJ; Stavrou T; Kun L; Wisoff J; Russo C; Geyer R; Phillips P; Kieran M; Greenberg M; Goldman S; Hyder D; Heideman R; Jones-Wallace D; August GP; Smith SH; Moshang T
    J Clin Oncol; 2001 Jan; 19(2):480-7. PubMed ID: 11208842
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumour surveillance imaging in patients with extrapituitary tumours receiving growth hormone replacement.
    Chung TT; Drake WM; Evanson J; Walker D; Plowman PN; Chew SL; Grossman AB; Besser GM; Monson JP
    Clin Endocrinol (Oxf); 2005 Sep; 63(3):274-9. PubMed ID: 16117814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term Effects of Growth Hormone Replacement Therapy in Childhood-onset Craniopharyngioma: Results of the German Craniopharyngioma Registry (HIT-Endo).
    Boekhoff S; Bogusz A; Sterkenburg AS; Eveslage M; Müller HL
    Eur J Endocrinol; 2018 Oct; 179(5):331-341. PubMed ID: 30139824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Growth Hormone Therapy Does Not Increase the Risk of Craniopharyngioma and Nonfunctioning Pituitary Adenoma Recurrence.
    Losa M; Castellino L; Pagnano A; Rossini A; Mortini P; Lanzi R
    J Clin Endocrinol Metab; 2020 May; 105(5):. PubMed ID: 32112101
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of 18-month of growth hormone (GH) replacement therapy in patients with Sheehan's syndrome.
    Tanriverdi F; Unluhizarci K; Kula M; Guven M; Bayram F; Kelestimur F
    Growth Horm IGF Res; 2005 Jun; 15(3):231-7. PubMed ID: 15921942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of GH substitution therapy in deficient adults on the recurrence rate of hormonally inactive pituitary adenomas: a case control study.
    Buchfelder M; Kann PH; Wüster C; Tuschy U; Saller B; Brabant G; Kleindienst A; Nomikos P;
    Eur J Endocrinol; 2007 Aug; 157(2):149-56. PubMed ID: 17656592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analyses of treatment variables for patients with childhood craniopharyngioma--results of the multicenter prospective trial KRANIOPHARYNGEOM 2000 after three years of follow-up.
    Müller HL; Gebhardt U; Schröder S; Pohl F; Kortmann RD; Faldum A; Zwiener I; Warmuth-Metz M; Pietsch T; Calaminus G; Kolb R; Wiegand C; Sörensen N;
    Horm Res Paediatr; 2010; 73(3):175-80. PubMed ID: 20197669
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progression of pituitary tumours: impact of GH secretory status and long-term GH replacement therapy.
    Gasco V; Caputo M; Cambria V; Beccuti G; Caprino MP; Ghigo E; Maccario M; Grottoli S
    Endocrine; 2019 Feb; 63(2):341-347. PubMed ID: 30341707
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sex Differences in Long-Term Safety and Tolerability of GH Replacement Therapy in GH Deficient Adults.
    Slagboom TNA; van Bunderen CC; van der Lely AJ; Drent ML
    J Clin Endocrinol Metab; 2023 Jun; 108(7):e415-e424. PubMed ID: 36652411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term effects of growth hormone replacement therapy on liver function in adult patients with growth hormone deficiency.
    Matsumoto R; Fukuoka H; Iguchi G; Nishizawa H; Bando H; Suda K; Takahashi M; Takahashi Y
    Growth Horm IGF Res; 2014 Oct; 24(5):174-9. PubMed ID: 25116471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.